B&B Triplewall (BBTCL)

FairStock Score: 28/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 25.92% and profit growth of 174.74% show strong momentum.
• Promoter holding of 73.76% aligns management interests with minority shareholders.
• Piotroski F-Score of 7/9 suggests improving financial fundamentals.
• Latest quarter sales of ₹155 Cr indicate ongoing operating traction.
• PEG ratio of 0.37 makes the high P/E look less expensive if growth persists.

Concerns

• Debt/Equity of 1.99 and ROCE of 2.98% signal high leverage and weak capital efficiency.
• P/E of 37.43 leaves very little margin of safety.
• ROE of 9.63% is below the level expected from a quality compounding business.
• Zero dividend means investors rely entirely on execution and share price appreciation.

AI Analysis

Let's look at B&B Triplewall as an investment, not a stock quote. It's in packaging, a business I would circle cautiously. Packaging can be decent, but it is often competitive, capital-intensive, and customers can squeeze pricing power. B&B is growing fast—sales up 25.92%, profit up 174.74%—and the latest quarter shows ₹155 Cr of sales translating to just ₹5 Cr of net profit. That is a thin margin, roughly 3%. The P/E of 37.43 is rich, though the PEG of 0.37 tempts one to call it cheap. But remember: if growth requires endless capital, shareholders see little cash. ROCE of only 2.98% and debt/equity of 1.99 tell me this growth is being purchased with borrowed money and more capacity, not with economic magic. ROE of 9.63% is far below what I'd demand from a packaging player. Promoter holding of 73.76% is reassuring—they hold serious skin in the game—and a Piotroski F-score of 7 out of 9 says the financial position is improving. Still, a 37 P/E leaves almost no margin for error in a business with such low returns on invested capital. Graham would insist on margin of safety; at this price, I don't see it. I would keep this on the watchlist, not in the wallet. If the company converts growth into higher ROCE, reduces debt, and proves these earnings are not a cyclical sugar high, I would become more interested. For now, the growth catches the eye, but the underlying economics do not yet justify the price. Patience remains the wise course.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer